Akeso presents positive HARMONi-2 trial survival data at WCLC
September 14, 2026 | 15:44
Akeso presented positive overall survival results from its Phase III HARMONi-2 trial comparing ivonescimab to pembrolizumab in non-small cell lung cancer patients at the World Conference on Lung Cancer.
Mobile Version